Sign inJoin waitlistJoin the waitlist

Daphne Stewart

Section Chief of Women's Cancer · University of Southern California/Los Angeles General Medical Center

Credentials: · · · ·

History

Women's Cancer Section · University of Southern California/Los Angeles General Medical Center
Present
University of Southern California/Los Angeles General Medical Center
Present

Hematology and Medical Oncology
Ronald Reagan UCLA Medical Center
2002–2005
Ronald Reagan UCLA Medical Center
1999–2002
University of Southern California/Los Angeles General Medical Center
1998–1999
University of California
Columbia Univ Coll of Phys & Surgeons
1994–1998

Research

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Journal of the National Comprehensive Cancer Network · 2022 · 346 citations
Differentiation therapy of leukemia: 3 decades of development
Review · Blood · 2009 · 278 citations
Networking antioxidants in the isolated rat heart are selectively depleted by ischemia-reperfusion
Free Radical Biology and Medicine · 1998 · 112 citations

Yuan Yuan
12 papers
JM
Joanne Mortimer
11 papers
MC
Mihaela Cristea
10 papers
EW
Edward Wang
8 papers
JW
James Waisman
8 papers
TD
Thanh Dellinger
8 papers
Mina Sedrak
6 papers
EH
Ernest Han
5 papers
LK
Laura Kruper
5 papers
Mustafa Raoof
5 papers
SL
Sayeh Lavasani
5 papers
VM
Victor Marder
5 papers

Clinical trials

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
Principal investigator · Recruiting · Phase 1
University of Southern California
2024–2028
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Site PI · Recruiting · Phase 2
Eli Lilly and Company
2026–2029
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2033
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Site PI · Recruiting · Phase 3
Stemline Therapeutics, Inc.
2024–2032